Feb 20 (Reuters) - Vascular Biogenics Ltd:
* VBL THERAPEUTICS ANNOUNCES THE LAUNCH OF A NEW CLINICAL TRIAL OF VB-111 COMBINED WITH THE CHECKPOINT INHIBITOR, NIVOLUMAB, IN METASTATIC COLORECTAL CANCER
* VASCULAR BIOGENICS LTD - NATIONAL CANCER INSTITUTE WILL SERVE AS INVESTIGATIONAL NEW DRUG (IND) SPONSOR FOR THIS STUDY Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.